Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Christine Haie-Meder; Petronella B Ottevanger; Jonathan A Ledermann; Pearly Khaw; Alessandro Colombo; Anthony Fyles; Marie-Helene Baron; Henry C Kitchener; Hans W Nijman; Roy F Kruitwagen; Remi A Nout; Karen W Verhoeven-Adema; Vincent T Smit; Hein Putter; Carien L Creutzberg

Journal article

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, Marie-Helene Baron, Henry C Kitchener, Hans W Nijman, Roy F Kruitwagen, Remi A Nout, Karen W Verhoeven-Adema, Vincent T Smit, Hein Putter, Carien L Creutzberg

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016

DOI: 10.1016/S1470-2045(16)30120-6

University of Melbourne Researchers

Linda Mileshkin Author Medical Education

Grants

Awarded by Cancer Research UK

Funding Acknowledgements

Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council, Project Grant, Cancer Australia Grant, Italian Medicines Agency, and Canadian Cancer Society Research Institute.